pubmed.ncbi.nlm.nih.gov

Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance - PubMed

Affiliations

  • PMID: 16259219

Review

Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance

Martin Haluzik. Curr Opin Investig Drugs. 2005 Oct.

Abstract

Adiponectin is a protein hormone produced exclusively by adipocytes. Its circulating levels are decreased in individuals with obesity, atherosclerosis and insulin resistance, suggesting that its deficiency may have a causal role in the etiopathogenesis of these diseases. Studies have shown that adiponectin administration in rodents has insulin-sensitizing, anti-atherogenic and anti-inflammatory effects and under certain settings also decreases body weight. Therefore, adiponectin replacement in humans may represent a promising approach to prevent and/or treat obesity, insulin resistance and type 2 diabetes; however, clinical studies with adiponectin administration need to be conducted to confirm this hypothesis. Current experimental and clinical data regarding adiponectin physiology and pathophysiology are detailed in this review.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources